Peer-reviewed veterinary case report
New skin cream tested for treating dog eczema and itching
By Fernandes, Beatriz et al.·Published in Veterinary dermatology·2026·Faculty of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A Novel Topical Emollient Plus for Canine Atopic Dermatitis: A Clinical Trial Assessing Efficacy and User Acceptance.
- Species:
- dog
Plain-English summary
A group of 21 dogs with atopic dermatitis, a common skin condition that causes itching and irritation, were treated with a new topical emollient designed to improve skin health. After 30 days of daily application, the dogs showed significant improvements in itching and skin lesions, and their skin barrier function also improved. Most owners reported high satisfaction with the treatment, rating its effectiveness as 'good to excellent.' This new emollient could be a helpful option for managing atopic dermatitis in dogs, but more studies are needed to confirm its benefits.
People also search for: dog itching treatment · atopic dermatitis in dogs · best emollient for dog skin problems
Abstract
BACKGROUND: Canine atopic dermatitis (cAD) is a common, chronic skin condition characterised by epidermal barrier dysfunction, immune dysregulation and cutaneous dysbiosis. While 'emollient plus' formulations are widely used in human atopic dermatitis (hAD), their role in cAD remains underexplored. HYPOTHESIS/OBJECTIVES: To evaluate the clinical efficacy and owner-perceived value of a novel emollient plus formulation as a co-adjuvant treatment for cAD. ANIMALS: Twenty-one client-owned dogs with controlled, nonseasonal cAD completed the study. MATERIALS AND METHODS: A proof-of-concept, bench-to-bedside study was conducted over 30 days. Dogs received a once-daily application of a novel emollient plus formulation developed in-house. Clinical outcomes were assessed using pruritus Visual Analog Scale (pVAS)10 and Canine Atopic Dermatitis Extent and Severity Index (CADESI)-04 scores, alongside skin barrier function parameters (trans epidermal water loss [TEWL] and pH) at the pinnae and inguinal areas. Owners evaluated therapeutic efficacy via the Owner Global Assessment of Treatment Efficacy (OGATE) questionnaire and sensorial acceptability through a survey. RESULTS: Significant reductions were observed in pVAS10 (4.25 ± 1.85 to 3.38 ± 1.79; p = 0.016) and CADESI-04 (24.62 ± 18.48 to 13.43 ± 7.44; p = 0.02) scores. TEWL (18.63 ± 17.33 to 9.56 ± 10.75; p = 0.049) and pH (6.07 ± 0.97 to 5.41 ± 0.71; p = 0.01) only had significant reductions at the pinnae. Owner satisfaction was exceptionally high, with 90.47% rating treatment efficacy as 'good to excellent'. The sensorial properties of the formulation also received consistently positive ratings. CONCLUSIONS AND CLINICAL RELEVANCE: This cAD-targeted emollient product demonstrated promising efficacy in reducing pruritus and skin lesions while possibly improving skin barrier function. Its favourable safety profile and high owner satisfaction suggest strong potential for routine clinical use in the management of cAD. Further controlled studies are warranted to confirm efficacy and optimised treatment protocols.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41194653/